NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: INFINIUM · data 2026-10-31
Infinium Pharmachem Ltd.
In plain words
Price: 13.4% below its 52-week high of ₹324.5.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹190 cr |
| Net profit (last 12 months) | ₹12 cr |
| Sales growth, 3 years (yearly) | 18.4% |
| Profit growth, 3 years (yearly) | 8.6% |
At a glance
P/E 36.0, P/B 3.6, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 10.5%, ROCE 13.5%, operating margin 9.8%: how much profit it earns on the money it uses.
Debt/equity 0.19, Profit growth 8.6% and sales growth 18.4% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Infinium Pharmachem Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.19.
What is Infinium Pharmachem Ltd.'s P/E ratio?
About 36, based on the last 12 months' earnings and a price of ₹281 (data 2026-10-31).
What is the 52-week high and low of Infinium Pharmachem Ltd.?
The 52-week high is ₹324.5 and the 52-week low is ₹189.4.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Infinium Pharmachem Ltd. | ₹281 | ₹438 cr | 36 | 3.6 | 10.5% | 13.5% | 0.19 | +8.0% |
| Amanta Healthcare Limited | ₹163.56 | ₹632 cr | 43.3 | — | 9.4% | 11.5% | 1.11 | +33.5% |
| Praveg Limited | ₹204.91 | ₹539 cr | — | — | -2.5% | 1.6% | 0.38 | -24.4% |
| Albert David Ltd | ₹762.8 | ₹435 cr | 19.3 | — | -0.4% | 0.3% | 0.08 | -11.0% |
| Jenburkt Pharmaceuticals Ltd | ₹853.6 | ₹377 cr | 11.5 | — | 18.8% | 22.7% | 0.01 | -18.1% |
| Medicamen Biotech Limited | ₹256.2 | ₹347 cr | 31.3 | — | 3.9% | 5.5% | 0.18 | -27.6% |
Compare INFINIUM with AMANTA in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open INFINIUM in NSE Scanner →